IL-22 Is an Intestinal Stem Cell Growth Factor, and IL-22 Administration in Vivo Reduces Morbidity and Mortality in Murine GvHD
Lindemans C, Mertelsmann A, O’Connor M, Dudakov J, Jenq R, Velardi E, Young L, Smith O, Lawrence G, Luo N, Ivanov J, Hua G, Martin M, Liu C, Kolesnick R, Van Den Brink M, Hanash A. IL-22 Is an Intestinal Stem Cell Growth Factor, and IL-22 Administration in Vivo Reduces Morbidity and Mortality in Murine GvHD. Blood 2014, 124: 651. DOI: 10.1182/blood.v124.21.651.651.Peer-Reviewed Original ResearchInnate lymphoid cellsIL-22 administrationIL-22Small intestineLymphoid cellsGut GVHDGrowth factorAllogeneic hematopoietic stem cell transplantationDay sevenWild-type B6 miceHematopoietic stem cell transplantationStroma-derived growth factorsAllo-HSCT modelClinical GVHD scoresExpansion of Lgr5Post-transplant immunodeficiencyStem cell transplantationNumber of Lgr5Paneth cell numbersGut microbial floraCell growth factorMechanism of actionGVHD pathologyGVHD scoresReduces Morbidity